← Back to Search

Tyrosine Kinase Inhibitor

Targeted Cancer Drugs for Cancer (CAPTUR Trial)

Phase 2
Recruiting
Research Sponsored by Canadian Cancer Trials Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have normal organ function as follows: Absolute neutrophil count: ≥ 1.5 x 10^9/L for solid tumours; ≥ 1.0 x 10^9/L for neurologic malignancies, Platelets ≥ 75 x 10^9/L (or ≥ 50 x 10^9/L if bone marrow involvement by myeloma or lymphoma), Total bilirubin ≤ 1.5 x UNL, AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal value unless liver metastases are present in which case they must be < 5 x ULN, Serum creatinine ≤ 1.5 x UNL or calculated or measured creatinine clearance ≥ 50mg/min/1.73µ^2, Patients must have measurable disease, Results must be available from tumour genomic or protein expression testing (if used to identify genetic variants), from one of the initiatives / groups listed in protocol Appendix VII, Patient consent (Main Study Consent for the screening step) must be appropriately obtained in accordance with applicable local and regulatory requirements, Patients must be accessible for treatment and follow-up, Women/men of childbearing potential must have agreed to use a highly effective contraceptive method
ECOG performance status 0-2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights

CAPTUR Trial Summary

This trial will study the effects of targeted cancer drugs on patients with specific gene changes.

Who is the study for?
Adults with incurable metastatic solid tumors, multiple myeloma, or B cell non-Hodgkin lymphoma without standard life-prolonging treatment options. Participants must be over 18, have an ECOG performance status of 0-2, normal organ function and measurable disease. They should agree to use effective contraception and not have other conditions that could affect the trial's safety or results.Check my eligibility
What is being tested?
The CAPTUR study is testing targeted therapy drugs on patients with specific abnormal gene changes in their cancer. These therapies aim at the genetic level to block cancer growth and spread. The trial includes a variety of drugs like Erlotinib and Nivolumab plus Ipilimumab among others.See study design
What are the potential side effects?
Potential side effects depend on the drug given but may include fatigue, skin reactions, digestive issues, blood count changes, liver function alterations and increased risk of infections. Some drugs might also cause heart problems or interfere with wound healing.

CAPTUR Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and am up and about more than half of the day.
Select...
I am an adult with an incurable cancer (not brain cancer) and no life-prolonging treatment options or have refused them.

CAPTUR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective response rate defined as the number of patients with complete response or partial response
Secondary outcome measures
Number and severity of adverse events grade >3, or of lesser grade resulting in discontinuation, delay or reduction in dose of study drug
Progression-free survival by disease-appropriate objective criteria

CAPTUR Trial Design

14Treatment groups
Experimental Treatment
Group I: Group 9 Arm CLOSEDExperimental Treatment1 Intervention
CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL
Group II: Group 8Experimental Treatment1 Intervention
CDKN2A, CDK4, CCND1, SMARCA4
Group III: Group 7Experimental Treatment1 Intervention
BRCA1, BRCA2, mutations in HRD
Group IV: Group 6 - Arm CLOSEDExperimental Treatment1 Intervention
high mutation burden, POLE, POLD1
Group V: Group 5Experimental Treatment1 Intervention
EGFR
Group VI: Group 4 - Arm CLOSED, no patients recruitedExperimental Treatment1 Intervention
KIT, PDGFRA, PDGFRB, ABL1
Group VII: Group 3 - Arm CLOSEDExperimental Treatment1 Intervention
ALK, ROS1, MET
Group VIII: Group 2 - Arm CLOSED, no patients recruitedExperimental Treatment1 Intervention
BCR-ABL, SRC
Group IX: Group 14Experimental Treatment1 Intervention
ERBB2
Group X: Group 13Experimental Treatment1 Intervention
PTCH1, SMO
Group XI: Group 12Experimental Treatment1 Intervention
BRAFV600
Group XII: Group 11 - Arm CLOSEDExperimental Treatment1 Intervention
ERBB2
Group XIII: Group 10Experimental Treatment1 Intervention
AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2
Group XIV: Group 1 - Arm CLOSED, no patients recruitedExperimental Treatment1 Intervention
VEGFR1, VEGFR2, VEGFR3
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vismodegib
2015
Completed Phase 4
~1880
Axitinib
2020
Completed Phase 2
~3050
Bosutinib
2015
Completed Phase 3
~2390
Erlotinib
2011
Completed Phase 4
~2290
Olaparib
2007
Completed Phase 4
~2140
Tucatinib
2017
Completed Phase 2
~520
Dasatinib
2012
Completed Phase 3
~2320
Crizotinib
2014
Completed Phase 3
~2370
Palbociclib
2017
Completed Phase 3
~3710
Sunitinib
2014
Completed Phase 3
~4380
Temsirolimus
2008
Completed Phase 2
~1940

Find a Location

Who is running the clinical trial?

PfizerIndustry Sponsor
4,562 Previous Clinical Trials
10,906,861 Total Patients Enrolled
35 Trials studying Multiple Myeloma
8,634 Patients Enrolled for Multiple Myeloma
Seagen Inc.Industry Sponsor
206 Previous Clinical Trials
68,619 Total Patients Enrolled
8 Trials studying Multiple Myeloma
4,028 Patients Enrolled for Multiple Myeloma
Hoffmann-La RocheIndustry Sponsor
2,427 Previous Clinical Trials
1,088,431 Total Patients Enrolled
13 Trials studying Multiple Myeloma
1,765 Patients Enrolled for Multiple Myeloma

Media Library

Axitinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03297606 — Phase 2
Multiple Myeloma Research Study Groups: Group 6 - Arm CLOSED, Group 8, Group 3 - Arm CLOSED, Group 4 - Arm CLOSED, no patients recruited, Group 13, Group 2 - Arm CLOSED, no patients recruited, Group 1 - Arm CLOSED, no patients recruited, Group 9 Arm CLOSED, Group 7, Group 10, Group 11 - Arm CLOSED, Group 14, Group 12, Group 5
Multiple Myeloma Clinical Trial 2023: Axitinib Highlights & Side Effects. Trial Name: NCT03297606 — Phase 2
Axitinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03297606 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people are guinea pigs for this experiment?

"This trial requires 720 individuals that fit the pre-determined inclusion criteria. These patients can be recruited from various hospitals, including The Jewish General Hospital in Montreal, Quebec and London Regional Cancer Program in London, Saskatchewan."

Answered by AI

What type of cancer do doctors most often prescribe Nivolumab plus Ipilimumab for?

"Nivolumab in conjunction with Ipilimumab can be used to shrink and manage thyroid cancers, metastatic basal cell carcinoma (bcc), as well as malignant neoplasms."

Answered by AI

How many different locations are conducting this trial?

"There are 9 different clinical sites running this trial, with locations in Montreal, London and Saskatoon. To limit travel as much as possible, patients should select the nearest location to them when enrolling."

Answered by AI

Are we looking for more individuals to participate in this experiment?

"The study is currently looking for new participants, with the date of the clinical trial's posting being October 6th, 2017 and the most recent update on November 14th, 2022."

Answered by AI

What are the most severe side effects that have been seen in patients taking Nivolumab and Ipilimumab?

"Nivolumab plus Ipilimumab falls into Phase 2 of clinical trials, meaning that while there is some evidence backing its safety, no such data exists to support efficacy. As a result, our team at Power have given it a score of 2."

Answered by AI

Could you please tell me if Nivolumab has been tested in combination with other drugs?

"The first study of nivolumab plus ipilimumab was completed in 1999. Since then, there have been 1995 similar studies published with 1566 currently active. A high concentration of these ongoing trials is based out of the Canadian city Montreal, Quebec."

Answered by AI
~169 spots leftby Jan 2026